SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
356.60
+0.10 (0.03%)
Aug 21, 2026, 3:29 PM IST
SMS Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 33,396 | 35,105 | 18,863 | 15,089 | 4,931 | 7,915 | |
Market Cap Growth | 57.81% | 86.10% | 25.01% | 206.01% | -37.70% | -24.75% |
Enterprise Value | 36,586 | 37,352 | 21,626 | 17,527 | 7,463 | 10,083 |
Last Close Price | 356.60 | 374.85 | 212.49 | 177.81 | 57.96 | 92.73 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 32.29 | 34.42 | 27.29 | 30.28 | - | 12.72 |
PS Ratio | 3.72 | 3.96 | 2.41 | 2.13 | 0.95 | 1.52 |
PB Ratio | 4.25 | 4.47 | 2.95 | 2.81 | 1.07 | 1.68 |
P/TBV Ratio | 4.27 | 4.48 | 2.96 | 2.83 | 1.07 | 1.69 |
P/FCF Ratio | - | - | - | - | - | 44.44 |
P/OCF Ratio | 56.39 | 59.28 | 23.09 | 30.10 | 21.96 | 17.57 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 4.08 | 4.21 | 2.76 | 2.47 | 1.43 | 1.94 |
EV/EBITDA Ratio | 19.56 | 21.81 | 15.59 | 15.07 | 13.79 | 8.83 |
EV/EBIT Ratio | 25.12 | 28.44 | 20.62 | 20.51 | 32.88 | 12.14 |
EV/FCF Ratio | - | - | - | - | - | 56.61 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.47 | 0.47 | 0.49 | 0.52 | 0.55 | 0.56 |
Debt / EBITDA Ratio | 2.10 | 2.13 | 2.23 | 2.40 | 4.64 | 2.29 |
Debt / FCF Ratio | - | - | - | - | - | 14.78 |
Net Debt / Equity Ratio | 0.41 | 0.41 | 0.42 | 0.46 | 0.54 | 0.46 |
Net Debt / EBITDA Ratio | 1.83 | 1.86 | 1.94 | 2.10 | 4.56 | 1.90 |
Net Debt / FCF Ratio | - | -4.47 | -6.46 | -120.21 | -33.02 | 12.17 |
Asset Turnover | - | 0.71 | 0.72 | 0.74 | 0.60 | 0.62 |
Inventory Turnover | - | 1.84 | 2.02 | 2.18 | 1.64 | 1.70 |
Quick Ratio | - | 0.74 | 0.80 | 0.86 | 0.68 | 0.58 |
Current Ratio | - | 1.81 | 1.71 | 1.61 | 1.61 | 1.92 |
Return on Equity (ROE) | - | 14.31% | 11.76% | 10.00% | -1.52% | 14.13% |
Return on Assets (ROA) | - | 6.53% | 6.00% | 5.58% | 1.63% | 6.21% |
Return on Invested Capital (ROIC) | 9.29% | 10.19% | 9.12% | 8.58% | 3.26% | 12.54% |
Return on Capital Employed (ROCE) | - | 13.00% | 12.70% | 12.20% | 3.60% | 12.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.07% | 2.90% | 3.67% | 3.30% | -1.43% | 7.86% |
FCF Yield | -2.14% | -2.03% | -2.21% | -0.14% | -1.52% | 2.25% |
Dividend Yield | 0.11% | 0.11% | 0.19% | 0.22% | 0.52% | 0.32% |
Payout Ratio | - | 3.48% | 4.90% | 5.10% | - | 4.08% |
Buyback Yield / Dilution | -8.12% | -3.18% | -4.72% | 0.00% | - | - |
Total Shareholder Return | -8.00% | -3.07% | -4.54% | 0.22% | 0.52% | 0.32% |